TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LEVULAN

AMINOLEVULINIC ACID HYDROCHLORIDE
Oncology Approved 1999-12-03
3
Indications
--
Phase 3 Trials
26
Years on Market

Details

Status
Prescription
First Approved
1999-12-03
Routes
TOPICAL
Dosage Forms
SOLUTION

Companies

LEVULAN Approval History

Loading approval history...

What LEVULAN Treats

1 indications

LEVULAN is approved for 1 conditions since its original approval in 1999. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Glioma
Source: FDA Label

Drugs Similar to LEVULAN

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVULAN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery.

LEVULAN Patents & Exclusivity

Latest Patent: Jan 2038

Patents (10 active)

US11690914 Expires Jan 12, 2038
US11077192 Expires Jan 12, 2038
US12296011 Expires Jan 12, 2038
US10357567 Expires Jan 12, 2038
US11571478 Expires Jan 12, 2038
US11135293 Expires Jan 12, 2038
US11446512 Expires Jan 17, 2037
US12290700 Expires Oct 13, 2036
US11697028 Expires Oct 13, 2036
US11179574 Expires Oct 13, 2036
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.